Skip to content
In English |
En español
National Cancer Institute
at the National Institutes of Health
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Popular Resources
Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-5 of 5 for your search:
Drug:
elacytarabine
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP4055-106
, NCT00405743
2.
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP4055-204
, NCT00831636
3.
Clinical Study of Previously Untreated Patients With Malignant Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP4055-201
, NCT00232726
4.
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP4055-202
, Grantor: CDER, IND/IDE Number: NA, NCT00498407
5.
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP4055-203
, NCT00498836
Select All on Page
Help with Results
We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat
NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map
Other Versions of this Site:
Mobile
|
Español
Follow Us:
Twitter
YouTube
Facebook
RSS
NIH…Turning Discovery Into Health
®
Mobile | Español
Mobile | Español
